Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology names Leila Alland interim CMO after Roger Sidhu's departure

Neutral Impact 3 of 5 leadership Written later

Cardiff Oncology said its Chief Medical Officer, Roger Sidhu, separated from the company on October 22, 2026, in a mutually agreed transition. The company appointed Dr. Leila Alland as interim Chief Medical Officer under a consulting agreement, and it also increased its authorized common stock to 300,000,000 shares. The filing does not include financial results or guidance.

Key points

  • Roger Sidhu separated from the company as Chief Medical Officer on October 22, 2026, in a mutually agreed transition.
  • Dr. Leila Alland's consulting agreement began October 23, 2026, and runs until April 22, 2027, or earlier if all services are completed.
  • Dr. Alland will be paid a monthly fee of $35,000 and will devote up to 50% of her professional time to the role.
  • Authorized common stock was increased to 300,000,000 shares, effective October 22, 2026.

The filing

CompanyCardiff Oncology, Inc. (CRDF)
Form8-K, current report
Filed with the SECOct 27, 2026, 4:44 PM ET
Accession number0001493152-26-048720

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.